DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

OrPro (ORP-100)

Pre-clinical

Pre-clinical

Therapeutic Approach

Mucociliary Clearance

This program is studying a modified form of thioredoxin, a type of protein that is thought to thin mucus in the lungs and may improve mucus clearance from the CF airway. 

Status

Laboratory studies to develop and test this compound are underway. 

Sponsor

This program is sponsored by OrPro Therapeutics and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). 

Contact us about OrPro (ORP-100) >